Search
Metamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawnApprovals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).
Categories: Analgesics, Non-NarcoticPascopyrum smithii pollen
go.drugbank.com/drugs/DB10719ApprovedPascopyrum smithii pollen is the pollen of the Pascopyrum smithii plant. Pascopyrum smithii pollen is mainly used in allergenic testing.
Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic ExtractBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects.
Categories: Non-Selective Calcium Channel BlockersNimesulide
go.drugbank.com/drugs/DB04743ApprovedWithdrawnNimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties.
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalSafrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnSafrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.
Categories: Monoamine Oxidase Inhibitors, Non-SelectiveSemaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigational[L41335] On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. … [L46726] On August 15, 2025, the FDA granted Accelerated Approval for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis [L53901]
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is the second PCSK9 inhibitor on the market, first being alirocumab. … Evolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaPotassium nitrate
go.drugbank.com/drugs/DB11090ApprovedInvestigationalPotassium nitrate is an inorganic salt with a chemical formula of KNO3. It is a natural source of nitrate and has been used as a constituent for several different purposes, including food preservatives, fertilizers, tree stump removal, r...
Mixtures: DOLNI - K GEL CON FLUOR, DOLNI-K GEL CON FLUORUROCasirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigational[A224429] These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape. … [A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older.